Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41488
Title: Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Authors: 
Keywords: 
Mesh: 
Issue Date: Oct-2017
Citation: Ann. Rheum. Dis..2017 Oct;(76)10:1679-1687
Abstract: ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab.
PMID: 28584187
URI: https://hdl.handle.net/20.500.12530/41488
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
PMC5629940.pdf1.62 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.